Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 3/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | GPR183 | P32249 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19615467 | 0.91 | USP2 (0.46) | USP2SMN1; SMN2CYP11B2HPGDEPHX2 | |
| SCHEMBL18588149 | 0.89 | USP2 (0.40) | USP2SMN1; SMN2CYP11B2RORCHPGD | |
| SCHEMBL19615485 | 0.82 | USP2 (0.41) | USP2SMN1; SMN2CYP11B2RORCUSP30 | |
| SCHEMBL21458082 | 0.82 | USP2 (0.41) | USP2SMN1; SMN2CYP11B2RORCUSP30 | |
| SCHEMBL22983614 | 0.82 | USP2 (0.42) | USP2SMN1; SMN2CYP11B2RORCUSP30 | |
| SCHEMBL2378427 | 0.82 | USP2 (0.42) | USP2SMN1; SMN2CYP11B2RORCUSP30 | |
| SCHEMBL18587326 | 0.79 | USP2 (0.46) | USP2SMN1; SMN2HPGDEPHX2 | |
| SCHEMBL475749 | 0.78 | USP2 (0.47) | USP2SMN1; SMN2CYP11B2RORCUSP30 | |
| SCHEMBL30254327 | 0.76 | USP2 (0.46) | USP2SMN1; SMN2CYP11B2RORCUSP30 | |
| SCHEMBL12445300 | 0.76 | USP2 (0.46) | USP2SMN1; SMN2CYP11B2RORCUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190315731-A1 | 6-(BUTA-1,3-DIYN-1-YL)BENZO[D]THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS, LTD. (CH) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315731-A1 | 6-(BUTA-1,3-DIYN-1-YL)BENZO[D]THIAZOLE DERIVATIVES | TMBIM6, BTN3A1, BET1 | USP2 4835/4885SMN1; SMN2 2962/4885CYP11B2 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.